Helper T cells point the way to specific immunotherapy for autoimmune disease

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 3, 2009, Pages 159-166

  Hall, Andrew M ^a   Vickers, Mark A ^a   Barker, Robert N ^a   Erwig, Lars P ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Autoimmune; Autoimmune haemolytic anaemia; Cytokine; Helper T cell; Peptide therapy; Regulatory T cell

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIAPEP 277; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; OKT 4; PEPTIDE DERIVATIVE; RHESUS ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DESIGN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GENETIC SUSCEPTIBILITY; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOTHERAPY; NONHUMAN; REGULATORY T LYMPHOCYTE; RETICULOENDOTHELIAL SYSTEM; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTIGEN PRESENTATION; HUMANS; IMMUNOTHERAPY, ACTIVE; PEPTIDES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 73249144884     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909789007043     Document Type: Review

References (80)

1. Elson, C.J.; Barker, R.N. Helper T cells in antibody-mediated, organ-specific autoimmunity. Curr. Opin. Immunol., 2000, 12, 664-9.
2. Groux, H.; O'Garra, A.; Bigler, M.; Rouleau, M.; Antonenko, S.; de Vries, J.E.; Roncarolo, M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 1997, 389, 737-42.
3. Barker, R.N.; Vickers, M.A.; Ward, F.J. Controlling autoimmunity--Lessons from the study of red blood cells as model antigens. Immunol. Lett., 2007, 108, 20-6.
4. Sakaguchi, S.; Yamaguchi, T.; Nomura, T.; Ono, M. Regulatory T cells and immune tolerance. Cell, 2008, 133, 775-87.
5. Barker, R.N.; Hall, A.M.; Standen, G.R.; Jones, J.; Elson, C.J. Identification of T-cell epitopes on the Rhesus polypeptides in autoimmune hemolytic anemia. Blood, 1997, 90, 2701-15.
6. Hall, A.M.; Ward, F.J.; Vickers, M.A.; Stott, L.M.; Urbaniak, S.J.; Barker, R.N. Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood, 2002, 100, 4529-36.
7. th ed. Oxford: Blackwell Scientific Publication, 1993.
8. Landsteiner, K.; Levine, P. On the cold agglutinins in human serum. J. Immunol., 1926, 12, 441-60.
9. Petz, F.E.; Garrattay, G. Aquired haemolytic anaemias. USA: Churchill-Livingstone Inc, 1980.
10. Engelfriet, C.P.; von dem, Borne, A.E.G.Kr.; Beckers, D.; van der Meulen, F.W.; Fleer A.; Roos D.; Ouwehand, W.H. Seminar on immune mediated cell destruction. Immune destruction of red cells Basel: Karger, 1981, 93-130.
11. Sokol, R.J.; Hewitt, S. Autoimmune hemolysis: a critical review. Crit. Rev. Oncol. Hematol., 1985, 4, 125-54.
12. Garratty, G. Mechanisms of immune red cell destruction, and red cell compatibility testing. Hum. Pathol., 1983, 14, 204-12.
13. Oliveira, G.G.; Hutchings, P.R.; Roitt, I.M.; Lydyard, P.M. Production of erythrocyte autoantibodies in NZB mice is inhibited by CD4 antibodies. Clin. Exp. Immunol., 1994, 96, 297-302.
14. Chen, S.Y.; Takeoka, Y.; Ansari, A.A.; Boyd, R.; Klinman, D.M.; Gershwin, M.E. The natural history of disease expression in CD4 and CD8 gene-deleted New Zealand black (NZB) mice. J. Immunol., 1996, 157, 2676-84.
15. Perry, F.E.; Barker, R.N.; Mazza, G.; Day, M.J.; Wells, A.D.; Shen, C.R.; Schofield, A.E.; Elson, C.J. Autoreactive T cell specificity in autoimmune hemolytic anemia of the NZB mouse. Eur. J. Immunol., 1996, 26, 136-41.
16. Shen, C.R.; Youssef, A.R.; Devine, A.; Bowie, L.; Hall, A.M.; Wraith, D.C.; Elson, C.J.; Barker, R.N. Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. Blood, 2003, 102, 3800-6.
17. Coutelier, J.P.; Johnston, S.J.; El Idrissi, Me, Pfau, C.J. Involvement of CD4+ cells in lymphocytic choriomeningitis virus-induced autoimmune anaemia and hypergammaglobulinaemia. J. Autoimmun., 1994, 7, 589-99.
18. Naysmith, J.D.; Ortega-Pierres, M.G.; Elson, C.J. Rat erythrocyte-induced anti-erythrocyte autoantibody production and control in normal mice. Immunol. Rev., 1981, 55, 55-87.
19. Barker, R.N.; Elson, C.J. Multiple self epitopes on the Rhesus polypeptides stimulate immunologically ignorant human T cells in vitro. Eur. J. Immunol., 1994, 24, 1578-82.
20. Barker, R.N.; Shen, C.R.; Mazza, G.; Perry, F.E.; Hall, A.M.; Elson, C.J. T-cell subsets in autoimmune haemolytic anaemia. Biochem. Soc. Trans., 1997, 25, 312S.
21. Hall, A.M.; Cairns, L.S.; Phelps, R.G.; Vickers, M.A.; Barker, R.N. Characterisation of regulatory responses to human autoantigens. Scand. J. Immunol., 2001, 54(Suppl. 1), 56.
22. Barker, R.N.; de Sa Oliveira, G.G.; Elson, C.J.; Lydyard, P.M. Pathogenic autoantibodies in the NZB mouse are specific for erythrocyte band 3 protein. Eur. J. Immunol., 1993, 23, 1723-6.
23. Stellrecht-Broomhall, K.A. Evidence for immune-mediated destruction as mechanism for LCMV-induced anemia in persistently infected mice. Viral Immunol., 1991, 4, 269-80.
24. Stern, M.; Buser, A.S.; Lohri, A.; Tichelli, A.; Nissen-Druey, C. Autoimmunity and malignancy in hematology--more than an association. Crit. Rev. Oncol. Hematol., 2007, 63, 100-10.
25. Hamblin, T.J. Autoimmune complications of chronic lymphocytic leukemia. Semin. Oncol., 2006, 33, 230-9.
26. Hall, A.M.; Vickers, M.A.; McLeod, E.; Barker, R.N. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood, 2005, 105, 2007-15.
27. Gehrs, B.C.; Friedberg, R.C. Autoimmune hemolytic anemia. Am. J. Hematol., 2002, 69, 258-71.
28. Garvey, B. Rituximab in the treatment of autoimmune haematological disorders. Br. J. Haematol., 2008, 141, 149-69.
29. Leddy, J.P.; Falany, J.L.; Kissel, G.E.; Passador, S.T.; Rosenfeld, S.I. Erythrocyte membrane proteins reactive with human (warm-reacting) anti-red cell autoantibodies. J. Clin. Invest., 1993, 91, 1672-80.
30. Avent, N.D.; Reid, M.E. The Rh blood group system: a review. Blood, 2000, 95, 375-87.
31. Barker, R.N.; Gruffydd-Jones, T.J.; Stokes, C.R.; Elson, C.J. Identification of autoantigens in canine autoimmune haemolytic anaemia. Clin. Exp. Immunol., 1991, 85, 33-40.
32. de Sa Oliveira, G.G.; Izui, S.; Ravirajan, C.T.; Mageed, R.A.; Lydyard, P.M.; Elson, C.J.; Barker, R.N. Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice. Clin. Exp. Immunol., 1996, 105, 313-20.
33. Barker, R.N.; Casswell, K.M.; Elson, C.J. Identification of murine erythrocyte autoantigens and cross-reactive rat antigens. Immunology, 1993, 78, 568-73.
34. Mazza, G.; Day, M.J.; Barker, R.N.; Corato, A.; Elson, C.J. Quantitation of erythrocyte-bound IgG subclass autoantibodies in murine autoimmune haemolytic anaemia. Autoimmunity, 1996, 23, 245-55.
35. Liblau, R.S.; Singer, S.M.; McDevitt, H.O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today, 1995, 16, 34-8.
36. Roncarolo, M.G.; Battaglia, M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol., 2007, 7, 585-98.
37. Mosmann, T.R.; Coffman, R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 1989, 7, 145-73.
38. Mosmann, T.R.; Cherwinski, H.; Bond, M.W.; Giedlin, M.A.; Coffman, R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J. Immunol., 2005, 175, 5-14.
39. de Vries, J.E.; de Waal, Malefyt, R.;Yssel, H.; Roncarolo, M.G.; Spits, H. Do human TH1 and TH2 CD4+ clones exist? Res. Immunol., 1991, 142, 59-63.
40. Romagnani, S. Human TH1 and TH2 subsets: doubt no more. Immunol.Today, 1991, 12, 256-7.
41. Murray, J.S. How the MHC selects Th1/Th2 immunity. Immunol. Today, 1998, 19, 157-63.
42. O'Garra A.; Arai, N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol., 2000, 10, 542-50.
43. Kourilsky, P.; Truffa-Bachi, P. Cytokine fields and the polarization of the immune response. Trends Immunol., 2001, 22, 502-9.
44. Paul, W.E.; Seder, R.A. Lymphocyte responses and cytokines. Cell, 1994, 76, 241-51.
45. Bettelli, E.; Korn, T.; Kuchroo, V.K. Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol., 2007, 19, 652-7.
46. Harrington, L.E.; Hatton, R.D.; Mangan, P.R.; Turner, H.; Murphy, T.L.; Murphy, K.M.; Weaver, C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol., 2005, 6, 1123-32.
47. Weaver, C.T.; Harrington, L.E.; Mangan, P.R.; Gavrieli, M.; Murphy, K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity, 2006, 24, 677-88.
48. Kurowska-Stolarska, M.; Kewin, P.; Murphy, G.; Russo, R.C.; Stolarski, B.; Garcia, C.C.; Komai-Koma, M.; Pitman, N.; Li, Y.; Niedbala, W.; McKenzie, A.N.; Teixeira, M.M.; Liew, F.Y.; Xu, D. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol., 2008, 181, 4780-90.
49. Miller, A.M.; Xu, D.; Asquith, D.L.; Denby, L.; Li, Y.; Sattar, N.; Baker, A.H.; McInnes, I.B.; Liew, F.Y. IL-33 reduces the development of atherosclerosis. J. Exp. Med., 2008, 205, 339-46.
50. North, R.J.; Mackaness, G.B. Immunological control of macrophage proliferation in vivo. Infect. Immun., 1973, 8, 68-73.
51. Goerdt, S.; Orfanos, C.E. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity, 1999, 10, 137-42.
52. Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol., 2004, 22, 531-62.
53. Weiner, H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol.Today, 1997, 18, 335-43.
54. Mqadmi, A.; Zheng, X.; Yazdanbakhsh, K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood, 2005, 105, 3746-8.
55. Friedman, A.; Weiner, H.L. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. USA, 1994, 91, 6688-92.
56. Akbari, O.; Freeman, G.J.; Meyer, E.H.; Greenfield, E.A.; Chang, T.T.; Sharpe, A.H.; Berry, G.; DeKruyff, R.H.; Umetsu, D.T. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med., 2002, 8, 1024-32.
57. Hall, A.M.; Cairns, L.S.; Altmann, D.M.; Barker, R.N.; Urbaniak, S.J. Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood, 2005, 105, 2175-9.
58. Karachunski, P.I.; Ostlie, N.S.; Okita, D.K.; Conti-Fine, B.M. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 1997, 100, 3027-35.
59. Anderton, S.M.; Wraith, D.C. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur. J. Immunol., 1998, 28, 1251-61.
60. Staines, N.A.; Harper, N.; Ward, F.J.; Malmstrom, V.; Holmdahl, R.; Bansal, S. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol., 1996, 103, 368-75.
61. Hall, A.M.; Ward, F.J.; Shen, C.R.; Rowe, C.; Bowie, L.; Devine, A.; Urbaniak, S.J.; Elson, C.J.; Barker, R.N. Deletion of the dominant autoantigen in NZB mice with autoimmune hemolytic anemia: effects on autoantibody and T-helper responses. Blood, 2007, 110, 4511-7.
62. McFarland, H.F. Complexities in the treatment of autoimmune disease. Science, 1996, 274, 2037-8.
63. Faria, A.M.; Weiner, H.L. Oral tolerance. Immunol. Rev., 2005, 206, 232-59.
64. Cairns, L.S.; Phelps, R.G.; Bowie, L.; Hall, A.M.; Saweirs, W.W.; Rees, A.J.; Barker, R.N. The fine specificity and cytokine profile of T-helper cells responsive to the alpha3 chain of type IV collagen in Goodpasture's disease. J. Am. Soc. Nephrol., 2003, 14, 2801-12.
65. Barker, R.N.; Erwig, L.P.; Hill, K.S.; Devine, A.; Pearce, W.P.; Rees, A.J. Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin. Exp. Immunol., 2002, 127, 220-5.
66. Steinman, L. Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. Neurotherapeutics, 2007, 4, 661-5.
67. Jin, D.; Zhang, L.; Zheng, J.; Zhao, Y. The inflammatory Th 17 subset in immunity against self and non-self antigens. Autoimmunity, 2008, 41, 154-62.
68. Hall, A.M.; Urbaniak, S.J.; Barker, R.N. RhD epitopes recognised by human regulatory T-cells in vitro inhibit responses by HLA transgenic mice in vivo. Immunology, 2001, 104, 57.
69. Ward, F.J.; Hall, A.M.; Cairns, L.S.; Leggat, A.S.; Urbaniak, S.J.; M.A.; Barker, R.N. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood, 2008, 111, 680-7.
70. Phelps, R.G.; Turner, A.N.;Rees, A.J. Direct identification of naturally processed autoantigen-derived peptides bound to HLA-DR15. J. Biol. Chem., 1996, 271, 18549-53.
71. Ablamunits, V.; Elias, D.; Reshef, T.; Cohen, I.R. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J. Autoimmun., 1998, 11, 73-81.
72. Huurman, V.A.; van der Meide, P.E.; Duinkerken, G.; Willemen, S.; Cohen, I.R.; Elias, D.; Roep, B.O. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin. Exp. Immunol., 2008, 152, 488-97.
73. Evavold, B.D.; Allen, P.M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science, 1991, 252, 1308-10.
74. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J.A.; McFarland, H.F.; Martin, R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med., 2000, 6, 1167-75.
75. Vandenbark, A.A.; Morgan, E.; Bartholomew, R.; Bourdette, D.; Whitham, R.; Carlo, D.; Gold, D.; Hashim, G.; Offner, H. TCR peptide therapy in human autoimmune diseases. Neurochem. Res., 2001, 26, 713-30.
76. Vandenbark, A.A. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr. Drug Targets Inflamm. Allergy, 2005, 4, 217-29.
77. Vandenbark, A.A.; Culbertson, N.E.; Bartholomew, R.M.; Huan, J.; Agotsch, M.; LaTocha, D.; Yadav, V.; Mass, M.; Whitman, R.; Lovera, J.; Milano, J.; Theofan, G.; Chou, Y.K.; Offner, H.; Bourdette, D.N. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology, 2008, 123, 66-78.
78. Van Ginderachter, J.A.; Movahedi, K.; Hassanzadeh, G.G.; Meerschaut, S.; Beschin, A.; Raes, G.; De Baetselier, P. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology, 2006, 211, 487-501.
79. D'Arena, G.; Taylor, R.P.; Cascavilla, N.; Lindorfer, M.A. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocr. Metab. Immune. Disord. Drug Targets, 2008, 8, 62-8.
80. US Food & Drug Administration Website, Life threatening brain infection in patients with systemic lupus erythematosus after Rituxan treatment, http://www.fda.gov/cder/drug/advisory/rituximab. htm. [Accessed on: August 11th, 2008].